Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy
Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders
Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval
Goldgroup Accelerates Growth Strategy Following Transformational Merger; Company Advances Multi-Asset Drill Programs, Mine Development and Expansion Plans
Syntholene Energy Corp. Upsizes Private Placement to $2.0 Million and Announces Closing of First Tranche
